50% Covaxin efficacy may not be as bad as it seems

A study conducted by AIIMS has shown that two doses of Covaxin, the indigenous vaccine developed by Indian Council of Medical Research in collaboration with Bharat Biotech, is 50% effective in preventing symptomatic infection due to Covid-19. This is lower than the 77.8% efficacy claimed by Bharat Biotech after phase 3 trials of the vaccine.

from Delhi News: Latest Delhi News Headlines & Live Updates from Delhi - Times of India https://ift.tt/3r8WUxJ
via IFTTT